With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic disabling dependence or co-morbid state.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
37
oral medication taken once daily
Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine
Queen Mary Hospital
Hong Kong, Hong Kong
change in severity of Cannabis Use Disorder (CUD)
Change in severity of the cannabis use disorder for the 2 arms as defined by DSM-5
Time frame: 6 months
prevalence of Cannabis induced mood disorder
The prevalence of the cannabis induced disorder in both arms
Time frame: 6 months
Change in Hamilton anxiety (HAM-A) rating scale
To assess the change of anxiety severity of the two treatment arms using HAM-A for both treatment arms with cut-off of defining anxiety \>=14
Time frame: 6 months
Change in Hamilton depression (HAM-D) rating scale
To assess the change of depression severity of the two treatment arms using HAM-D for both treatment arms with cut-off of defining depression \>=8
Time frame: 6 months
Change in cognitive outcome
To assess the change in cognitive outcome using Frontal Assessment Battery in the two treatment arms
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.